All Posts Tagged With: "DVAX"
(DVAX) Dynavax Technologies Announces Favorable Data on Heplisav
Dynavax Technologies Corp. (DVAX) has announced that it intends to present a detailed analysis of safety data on Heplisav, the company’s most advanced pipeline candidate.
Dynavax provided encouraging...
(DVAX) Dynavax Technologies Corporation Reports Progress
Dynavax Technologies Corporation (DVAX) announced recently it has selected the molecule DV1179 for clinical development in its endosomal Toll-like Receptor (TLR) inhibitor collaboration with GlaxoSmithKline...
(DVAX) Dynavax Technologies Corporation Begins Large Hepatitis Study
Dynavax Technologies Corp. (DVAX) recently announced the commencement of a large-scale late-stage study of its hepatitis B vaccine (HBV) Heplisav. The trial will enroll 2,000 patients in Canada and the United...
(DVAX) Dynavax Technologies Corporation Buys Symphony Dynamo
Recently, Dynavax Technologies Corp. (DVAX) completed the acquisition of Symphony Dynamo, Inc. in a stock deal. Under this agreement, Dynavax issued 13 million shares of its common stock to Symphony. The...
(DVAX) Dynavax Technologies Gets Good News for its Hepatitis B Vaccine
Dynavax Technologies Corp. (DVAX) announced recently that it has received approval from the European Union to make part of its hepatitis B vaccine (HBV) Heplisav at a German factory. The EU approval permits...
(DVAX) Dynavax Technologies Completes Hep-B Enrollment
Recently, Dynavax Technologies Corp. (DVAX) announced the completion of enrollment for the first of three cohorts of patients receiving DV-601 hepatitis B (HBV) therapy in an open-label, dose-escalating early-stage...
(DVAX) Dynavax Technologies Resumes Hepatitis Study
Yesterday, Dynavax Technologies Corp. (DVAX) announced that it has resumed the late-stage registration trial of its hepatitis B (HBV) vaccine Heplisav in patients with chronic kidney disease. The trial will enroll 600 patients. Heplisav will be tested against...
(DVAX) Dynavax Technologies Resumes Hepatitis Study
Yesterday, Dynavax Technologies Corp. (DVAX) announced that it has resumed the late-stage registration trial of its hepatitis B (HBV) vaccine Heplisav in patients with chronic kidney disease. The trial will enroll 600 patients. Heplisav will be tested against...